Full Press Release Details
BETHESDA, Md., Oct. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making an invited keynote presentation entitled "Harnessing Immunity: A Personalised, Multi-Target Approach to Cancer" at the annual UK National Health Service (NHS) CancerCare Oncology Conference on Tuesday, October 6, at 11:30 a.m. UK time.
The CancerCare Conference brings together NHS leaders and clinicians, cancer alliances and other healthcare professionals from across the UK to discuss developments in cancer care, innovation and emerging treatments.
Dr. Bosch will discuss the new era of cancer vaccines, the need for personalized treatments, the unique capabilities of dendritic cell (DC) based cancer vaccines such as DCVax®, clinical trial results, potential combination treatments and related matters. The slide deck will be posted on the Northwest Biotherapeutics website after the NHS conference.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program involves DCVax®-L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.